Receive a weekly summary and discussion of the top papers of the week by leading researchers in the field.

In Annals of surgical oncology ; h5-index 71.0

BACKGROUND : Whether primary tumor surgery is better than no surgery in patients with de novo stage IV breast cancer remains controversial.

METHODS : This study combined prospective clinical trials and a multicenter cohort to evaluate the impact of locoregional surgery in de novo stage IV breast cancer. The GRADE approach was used to assess the quality of evidence in meta-analysis, and propensity score matching analysis was used in the cohort study. This study was registered with PROSPERO CRD42016043766 and ClinicalTrials.gov NCT04456855.

RESULTS : A total of 1110 patients from six trials and 353 patients from the cohort study were included. The meta-analysis showed that compared with no surgery, locoregional surgery did not prolong overall survival (hazard ratio [HR] = 0.90, P = 0.40; moderate-quality) but had a significantly longer locoregional progression-free survival (HR = 0.23, P < 0.001; moderate-quality). The subgroup analysis of solitary bone-only metastasis (HR = 0.47, P = 0.04; high-quality) resulted in prolonged overall survival. In the cohort study, locoregional surgery showed a survival benefit (HR = 0.63, P = 0.041) before matching, but not (HR = 0.84, P = 0.579) after matching. Patients with bone-only metastasis showed a survival advantage in surgery compared with no surgery before matching (HR = 0.36, P = 0.034) as well as after matching (HR = 0.18, P = 0.017).

CONCLUSIONS : This study indicated that locoregional surgery had a significantly longer locoregional progression-free survival than no surgery in de novo stage IV breast cancer, and patients with bone-only metastasis tended to show an overall survival benefit from surgery.

Yu Yunfang, Hong Huangming, Wang Ying, Fu Tuping, Chen Yongjian, Zhao Jianli, Chen Peixian, Cai Ruizhao, Tan Yujie, He Zifan, Ren Wei, Zhou Lihuan, Huang Junhao, Tang Jun, Ye Guolin, Yao Herui

2021-Feb-03